Insmed Incorporated (INSM)

NMS – Real Time Price. Currency in USD

116.00

+12.11 (11.66%)

At close: May 12, 2026, 4:00 PM EDT

120.90

+4.90 (4.22%)

After-hours: May 12, 2026, 7:59 PM EDT

08.05.2026

Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%

INSM stock plunges 23% after Q1 sales miss estimates despite 230% revenue growth and strong Brinsupri uptake.

07.05.2026

Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript

07.05.2026

Insmed Tanks On Its Most Important Launch; Why Analysts Remain Bullish

Insmed stock tanked Thursday after its new lung drug, Brinsupri, missed elevated buy-side expectations, though beat sell-side views.

07.05.2026

Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates

Insmed (INSM) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.9. This compares to a loss of $1.42 per share a year ago.

07.05.2026

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

— Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025— — ARIKAYCE ® (amikacin liposome inhalation suspension) Revenues of $98.1 Million for the First Quarter of 2026, Reflecting 6% Growth Over the First Quarter of 2025— —Company Reiterates 2026 BRINSUPRI Revenue Guidance of at Least $1 Billion and 2026 ARIKAYCE Revenue Guidance of $450 Million to $470 Million— — Phase 3b ENCORE Study of ARIKAYCE in Patients with MAC Lung Disease Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints— —Phase 3 PALM-PAH Study of TPIP in Patients with PAH Initiated in April 2026— BRIDGEWATER, N.J., May 7, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

06.05.2026

Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis

— Insmed's Educational Initiative, Suspect Bronchiectasis (Suspect BE), Aims to Elevate Recognition and Diagnosis of Bronchiectasis and Encourage Conversations with a Pulmonologist — — Bronchiectasis Symptoms Often Overlap with COPD or Asthma and May Go Unrecognized for Years, Highlighting the Need to Look Deeper at Respiratory Symptoms — — TV Personality, Ty Pennington, Brings Visibility to the Chronic Lung Condition Through His Experience Caring for His Mother, Who is Living with Bronchiectasis — BRIDGEWATER, N.J., May 6, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced a collaboration with Emmy® Award–winning TV host, designer, and carpenter, Ty Pennington, to launch Suspect Bronchiectasis (Suspect BE).

04.05.2026

Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026

—New Data in Non-Cystic Fibrosis Bronchiectasis Further Define Impact of BRINSUPRI ® on Respiratory Symptoms— —Findings from a Pharmacokinetic Study Continue to Support Further Evaluation of Treprostinil Palmitil Inhalation Powder Phase 3 Development Program— —Additionally, Insmed Provides Independent Research Grant to the American Thoracic Society for a Landmark Quality Initiative to Improve Diagnosis of Bronchiectasis across the U.S.— BRIDGEWATER, N.J., May 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will present six abstracts from across its respiratory portfolio and pipeline at the American Thoracic Society International Conference 2026 (ATS 2026), taking place May 17–20 in Orlando, Florida.

Videos

12.01.2026

Neutral

Insmed CEO Will Lewis talks its rare disease drug pipeline

18.12.2025

Negative

Mizuho's Jared Holz talks Insmed sinking double digits on sinus drug trial news

03.11.2025

Positive

Latest read on rare disease gene therapy from Insmed CEO Will Lewis

Press releases

07.05.2026

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

06.05.2026

Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis

07.04.2026

Insmed Provides Clinical Update on Phase 2b CEDAR Study

—Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program— —Safety Was Consistent with Previous Studies and No New Safety Signals Were Identified for Either Dose of Brensocatib— BRIDGEWATER, N.J., April 7, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the Phase 2b CEDAR study, which evaluated brensocatib in adult patients with moderate to severe hidradenitis suppurativa (HS), did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms.

23.03.2026

Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease

—The Study Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Improvements in Respiratory Symptom Score and Culture Conversion Rates— —In the Second Half of 2026, Insmed Plans to File a Supplemental NDA for ARIKAYCE with the FDA and Submit the Data to the PMDA in Japan to Support Potential Label Changes— —Insmed to Host Investor Conference Call on Monday, March 23, 2026, at 8:00 AM ET— BRIDGEWATER, N.J., March 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced positive topline results from the Phase 3b ENCORE study.

Insmed Incorporated (INSM)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Insmed Incorporated (INSM)

Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%

Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript

Insmed Tanks On Its Most Important Launch; Why Analysts Remain Bullish

Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis

Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026

Videos

Press releases

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis

Insmed Provides Clinical Update on Phase 2b CEDAR Study

Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease

Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%

Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript

Insmed Tanks On Its Most Important Launch; Why Analysts Remain Bullish

Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis

Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026

Videos

Press releases

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis

Insmed Provides Clinical Update on Phase 2b CEDAR Study

Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease

Search stocks

Insmed Incorporated (INSM)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Insmed Incorporated (INSM)

Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%

Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript

Insmed Tanks On Its Most Important Launch; Why Analysts Remain Bullish

Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis

Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026

Videos

Press releases

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis

Insmed Provides Clinical Update on Phase 2b CEDAR Study

Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease

Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%

Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript

Insmed Tanks On Its Most Important Launch; Why Analysts Remain Bullish

Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis

Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026

Videos

Press releases

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis

Insmed Provides Clinical Update on Phase 2b CEDAR Study

Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease